TrialmAbs2016
Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases.
Michela Silacci et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
47 papers cite it
this papercites it